Marpai (MRAI) Competitors $0.98 -0.08 (-7.31%) (As of 12/20/2024 04:04 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends MRAI vs. ENZ, CCM, PMD, TOI, BRTX, OPGN, KDLY, OTRK, MGRX, and VSEEShould you be buying Marpai stock or one of its competitors? The main competitors of Marpai include Enzo Biochem (ENZ), Concord Medical Services (CCM), Psychemedics (PMD), Oncology Institute (TOI), BioRestorative Therapies (BRTX), OpGen (OPGN), Kindly MD (KDLY), Ontrak (OTRK), Mangoceuticals (MGRX), and Vsee Health (VSEE). These companies are all part of the "healthcare" industry. Marpai vs. Enzo Biochem Concord Medical Services Psychemedics Oncology Institute BioRestorative Therapies OpGen Kindly MD Ontrak Mangoceuticals Vsee Health Marpai (NASDAQ:MRAI) and Enzo Biochem (NYSE:ENZ) are both small-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk. Do institutionals and insiders hold more shares of MRAI or ENZ? 49.8% of Marpai shares are held by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are held by institutional investors. 61.3% of Marpai shares are held by insiders. Comparatively, 11.4% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, MRAI or ENZ? Marpai has a beta of 4.93, suggesting that its stock price is 393% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Does the media favor MRAI or ENZ? In the previous week, Enzo Biochem had 6 more articles in the media than Marpai. MarketBeat recorded 6 mentions for Enzo Biochem and 0 mentions for Marpai. Marpai's average media sentiment score of 0.00 beat Enzo Biochem's score of -0.35 indicating that Marpai is being referred to more favorably in the media. Company Overall Sentiment Marpai Neutral Enzo Biochem Neutral Is MRAI or ENZ more profitable? Enzo Biochem has a net margin of -81.73% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat Enzo Biochem's return on equity.Company Net Margins Return on Equity Return on Assets Marpai-85.70% N/A -100.23% Enzo Biochem -81.73%-11.84%-8.31% Which has higher valuation and earnings, MRAI or ENZ? Enzo Biochem has lower revenue, but higher earnings than Marpai. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarpai$37.15M0.36-$28.75M-$2.64-0.37Enzo Biochem$30.31M1.31-$26.08MN/AN/A Do analysts prefer MRAI or ENZ? Marpai currently has a consensus target price of $6.00, suggesting a potential upside of 510.69%. Given Marpai's stronger consensus rating and higher probable upside, equities research analysts clearly believe Marpai is more favorable than Enzo Biochem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marpai 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in MRAI or ENZ? Enzo Biochem received 210 more outperform votes than Marpai when rated by MarketBeat users. However, 66.67% of users gave Marpai an outperform vote while only 54.78% of users gave Enzo Biochem an outperform vote. CompanyUnderperformOutperformMarpaiOutperform Votes266.67% Underperform Votes133.33% Enzo BiochemOutperform Votes21254.78% Underperform Votes17545.22% SummaryMarpai beats Enzo Biochem on 10 of the 16 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Marpai News Delivered to You Automatically Sign up to receive the latest news and ratings for MRAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRAI vs. The Competition Export to ExcelMetricMarpaihealth & allied services, not elsewhere classified IndustryBusiness SectorNASDAQ ExchangeMarket Cap$17.17M$1.91B$7.23B$9.08BDividend YieldN/A7.04%2.33%4.23%P/E Ratio-0.3715.5728.2917.18Price / Sales0.363.17406.37116.95Price / CashN/A9.7731.1337.86Price / Book-0.573.045.864.78Net Income-$28.75M$69.56M$126.23M$225.60M7 Day Performance-21.40%-1.73%4.03%-1.23%1 Month Performance-18.80%-2.76%8.84%3.36%1 Year Performance-49.62%-25.02%19.33%16.60% Marpai Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRAIMarpaiN/A$0.98-7.3%$6.00+510.7%-47.7%$17.17M$37.15M-0.37150Gap DownENZEnzo Biochem0.7773 of 5 stars$1.01-1.0%N/A-46.7%$52.77M$31.91M0.00520Earnings ReportAnalyst ForecastCCMConcord Medical Services0.3768 of 5 stars$4.89-1.2%N/A-58.8%$21.23M$471.70M0.00970Analyst ForecastNews CoverageGap DownPMDPsychemedics1.3983 of 5 stars$2.67-1.8%N/A-5.3%$15.73M$22.10M-5.24140Insider TradeGap DownHigh Trading VolumeTOIOncology Institute2.5303 of 5 stars$0.20-11.7%$2.50+1,170.3%-88.1%$14.87M$378.93M-0.29660BRTXBioRestorative Therapies3.455 of 5 stars$1.46+0.7%$18.00+1,132.9%-11.4%$10.10M$150,000.00-0.917OPGNOpGenN/A$1.07-3.6%N/A-82.8%$8.95M$3.42M0.00100Analyst ForecastNews CoverageGap DownKDLYKindly MDN/A$1.15-11.5%N/AN/A$6.87M$2.88M0.00N/AGap DownOTRKOntrak2.6135 of 5 stars$1.60-2.4%$45.00+2,712.5%-76.2%$6.75M$11.24M-0.15250Positive NewsMGRXMangoceuticals1.1789 of 5 stars$2.53-3.1%N/A-96.2%$6.29M$755,000.00-0.453News CoverageGap UpVSEEVsee HealthN/A$1.31-12.1%N/AN/A$4.72M$6.38M0.00N/ANews CoverageGap Down Related Companies and Tools Related Companies Enzo Biochem Competitors Concord Medical Services Competitors Psychemedics Competitors Oncology Institute Competitors BioRestorative Therapies Competitors OpGen Competitors Kindly MD Competitors Ontrak Competitors Mangoceuticals Competitors Vsee Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRAI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marpai, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marpai With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
